Hims & Hers Stock Dip and What It Means for Telehealth and Clinicians
… semaglutide shortage had been resolved. Semaglutide is the active ingredient in weight loss meds like Ozempic and Wegovy, and compounding is legal …
AbbVie gets into obesity with $350M deal for once-weekly shot | BioPharma Dive
If successful, these drugs could be used as alternatives to or in combination with marketed drugs like Novo’s Wegovy and Lilly’s Zepbound to increase …
How to trick the body’s metabolism: Mouse study reveals new path for weight-loss and diabetes treatments
Many people who have tried to lose weight by cutting calories are familiar with this frustrating reality: At some point, the body stops shedding pounds. It senses the reduced calorie intake and responds by slowing down metabolism, causing it to burn fewer calories than before the diet.
Semaglutide: A Promising Treatment for Alcohol Use Disorder – INSCMagazine
Semaglutide, a GLP-1 receptor agonist initially approved for type 2 diabetes and later for weight management, is now showing potential in treating …
Novo Nordisk Launches National “My Ozempic® Era” Campaign Celebrating Stories of …
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood …
Low-carb, low-fibre diets could raise risks of colon cancer – Toronto Star
Numerous studies have shown that a diet high in sugar and fat — a so-called “Western-style diet” — is linked to colorectal cancer, as well as obesity …
Targeted drug offers hope for safe, effective senolytic treatment for liver disease, cancer
… obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or …
Tesla, Broadcom, Strategy, Coinbase, Robinhood: Stocks to watch today – Quartz
Eli Lilly wants to replace Zepbound with an even stronger weight loss drug. Nvidia’s record earnings reveal just 3 customers make up 30% of revenue.
Semaglutide API Market, Global Outlook and Forecast 2024-2030 – WhaTech
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes and obesity. The growing …
Nutrigenomics Market Size, Share and Trends 2025 to 2034 – Precedence Research
… cancer, obesity, and cardiovascular diseases. North America has a … Obesity is a primary application area for nutrigenomics. The obesity …